BrightHeart, a Paris, France-based medical technology company developing artificial intelligence software focused on improving the detection of congenital heart defects in fetuses, raised €2M in Seed funding.
Sofinnova Partners made the investment.
The company intends to use the funds to bolster the development of the technology, prepare its regulatory submission(s), and facilitate its expansion.
Co-founded by Dr. Marilyne Levy and Dr. Bertand Stos, and also led by Chief Technology Officer Christophe Gardella, BrightHeart is a pre-clinical medical device company whose software uses artificial intelligence to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. Combined with access to a proprietary database of more than 20,000 fetal ultrasound exams, The technology leverages AI and expertise in fetal ultrasound cardiac imaging to help caregivers improve the detection of complex fetal heart defects in utero, during an ultrasound screening exam, when early interventions could either correct them or improve a child’s chance of survival.
Just a few months after its inception, the company, which is part of Sofinnova MD Start, the venture capital firm’s medical device accelerator, is finalizing a first version of its software, filed multiple patent applications in Europe and the U.S., engaged with regulators, and is actively working on the preparation of regulatory submissions for its first product in key geographies.
The company
FinSMEs
31/05/2023